Recent Report on Cyclin-Dependent Kinase 6Cell Division Protein Kinase 6 or EC 2.7.11.22-Pipeline Review, H1 2016

Cyclin-Dependent Kinase 6Cell Division Protein Kinase 6 or EC 2.7.11.22-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ Cyclin-Dependent Kinase 6Cell Division Protein Kinase 6 or EC 2.7.11.22-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report assesses Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 

- The report summarizes all the dormant and discontinued pipeline projects 

- The report reviews latest news and deals related to Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Beta Pharma, Inc. Eli Lilly and Company G1 Therapeutics, Inc. Jiangsu Hengrui Medicine Co., Ltd. Novartis AG Onconova Therapeutics, Inc. Pfizer Inc. Sihuan Pharmaceutical Holdings Group Ltd. Teijin Pharma Limited ViroStatics srl

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###